IL9 and B-cell chronic lymphocytic leukemia: Our results suggest that agents targeting IL-9, such as anti-IL-9 neutralizing antibodies, are plausible partners for combination therapies with immune checkpoint inhibitors to reverse the state of exhaustion and reinvigorate protective immune responses in CLL.